Call for collaboration for access to screening facilities for rationally selected compounds against SARS-CoV-2
Background: Exscalate4CoV (acronym E4C) is an EU-funded project that was selected after the emergency Call of expression of interest that the European Commission (DG RTD) issued on 31 January. The project will receive a 3 million EUR of EU funding in the next 18 months. It is consisting of a coalition of three of the most powerful supercomputing centres in the EU (CINECA in Italy, Barcelona supercomputing centre in Spain and Jülich supercomputing centre in Germany) together with a pharmaceutical company and several large Institutes dealing with biology and bio-molecular dynamics. The E4C team use supercomputers in the search of a therapies (small molecule drugs) against SARS-CoV-2 by complementing the classical trial and error clinical approach and possible experimentation in patients, by comparing the signature of the protein of the virus against active molecules that are used in existing databases of compounds. The project is currently processing digital models of the protein of the virus and is matching them against a publicly available database of thousands of known active antimolecules that are part of existing drugs with the aim to find out which combinations of active molecules could react to the virus.
The E4C project is also establishing a pipeline of phenotypic and target based screens to evaluate the efficacy of repurposed, commercial and de-novo designed compounds.
Read more on the attached call and visit the below link.